Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1148MR)

This product GTTS-WQ1148MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1148MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2756MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ4407MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ8018MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ14439MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ8138MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ4913MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ14888MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ11619MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MGD-006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW